KCM
ATNM icon

Kennedy Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Kennedy Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,778
Closed -$206K – 678
2023
Q2 		$206K Sell
27,778
-18,533
-40% -$158K ﹤0.01% 650
2023
Q1 		$438K Buy
+46,311
New +$489K 0.01% 570

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Kennedy Capital Management's ATNM Position: Q3 2023 in Review

Kennedy Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2023, closing a stake of 27,778 shares — an estimated $206K sold.

Kennedy Capital Management first reported a position in ATNM in Q1 2023 and held it in 2 quarters. The position peaked at $438K in Q1 2023. 58 funds tracked by Wall St. Rank hold ATNM as of Q3 2023.

  • Kennedy Capital Management reported no remaining Actinium Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 27,778 Actinium Pharmaceuticals shares in Q3 2023, an estimated $206K.
  • Kennedy Capital Management first reported a position in Actinium Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Kennedy Capital Management's Actinium Pharmaceuticals position peaked at $438K in Q1 2023.
  • 58 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2023.

Based on Kennedy Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.